Hyperfine, Inc.

NASDAQ:HYPR

Medical - Devices

Healthcare
$0.56 +15.65%

+$0.22 today

Market cap
$51.10M
Beta
1.38
P/E (TTM)
-4.5
EPS (TTM)
-$0.36
52W Low $0.66High $2.22

Volume 1.16M

Average 0.60M

HYPR Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Hyperfine, Inc.NASDAQ: HYPR

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 97.7M shares rose 29.1% year over year, ahead of the +18.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 3.7% from the prior quarter. Over 3 fiscal years it compounded at +10.2% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +29.1% holds above the trailing-twelve-month pace of +18.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
97.7M+3.7% QoQ
Last fiscal yearDec 2025
94.2M+30.1% YoY
LTMMar 2026
87.25M+18.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.1%——
1 year+30.1%——
3-year CAGR+10.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
94.2M USD
Year-over-year change
+30.1%
4-year CAGR
+7.6%

Weighted Avg Shares vs competitors

How HYPR compares with its peers on the latest reported figures

  • HYPR's LTM Mar 2026 weighted avg shares of 87.25M shares is the highest of the 7 companies compared; the peer median is 31.24M shares.
  • Its year-over-year change of +18.9% is the highest of 7, against a peer median of -0.9%.
  • Over three fiscal years its annual growth of +10.2% compares with a peer median of +1.7%.
HYPR Competitors Peer median
Weighted Avg Shares for HYPR and competitors
Company Period LTM YoY 3-year CAGR
HYPRHyperfine, Inc.LTM Mar 202687.25M +18.9%+10.2%
VANIVivani Medical, Inc.LTM Mar 202665.65M +15.7%+17.7%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
LUNGPulmonx CorporationLTM Mar 202641.11M +4.5%+3.1%
RCELAVITA Medical, Inc.LTM Mar 202621.36M -17.9%+3.7%
IMAImageneBio IncLTM Mar 202619.79M -59.0%-48.8%
FONRFONAR CorporationLTM Mar 20266.22M -2.6%-1.2%
Peer median (excluding HYPR) 31.24M-0.9%+1.7%

Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.5M6.81M11.03M12.89M13.56M
Cost of Revenue2.66M5.91M6.28M7M6.81M
Gross Profit(1.17M)907K4.76M5.89M6.75M
Gross Margin-78.0%13.3%43.1%45.7%49.8%
Research & Development25.84M28.16M22.49M22.5M17.45M
Selling, General & Admin37.86M46.63M30.38M26.62M26.39M
Operating Expenses63.7M74.78M52.87M49.12M43.84M
Depreciation & Amortization726K1.02M1.05M1.01M2.2M
EBITDA(64.13M)(72.15M)(43.18M)(39.71M)(33.37M)
EBITDA Margin-4286.4%-1058.8%-391.4%-308.1%-246.1%
Operating Income(64.87M)(73.87M)(48.12M)(43.22M)(37.09M)
Operating Margin-4336.1%-1084.2%-436.1%-335.3%-273.4%
Interest Income18K761K3.84M2.49M1.02M
Interest Expense00000
Other Income / Expenses17K710K3.88M2.5M1.51M
Income Before Tax(64.85M)(73.16M)(44.24M)(40.72M)(35.57M)
Pre-Tax Margin-4335.0%-1073.7%-401.0%-315.9%-262.3%
Income Tax Expense00000
Net Income(64.83M)(73.16M)(44.24M)(40.72M)(35.57M)
Net Margin-4333.8%-1073.7%-401.0%-315.9%-262.3%
EPS (Basic)(0.92)(1.04)(0.62)(0.56)(0.43)
EPS (Diluted)(0.92)(1.04)(0.62)(0.56)(0.43)
Weighted Avg Shares70.33M70.45M71.32M72.41M94.2M
Weighted Avg Shares (Diluted)70.33M70.45M71.32M72.41M94.2M

Hyperfine, Inc.

NASDAQ:HYPR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.